242 related articles for article (PubMed ID: 29885868)
1. Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: Mortality and prognostic factors.
Callejas-Díaz A; Fernández-Pérez C; Ramos-Martínez A; Múñez-Rubio E; Sánchez-Romero I; Vargas Núñez JA
Med Clin (Barc); 2019 Feb; 152(3):83-89. PubMed ID: 29885868
[TBL] [Abstract][Full Text] [Related]
2. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
[TBL] [Abstract][Full Text] [Related]
3. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
[TBL] [Abstract][Full Text] [Related]
4. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.
Dantas RC; Ferreira ML; Gontijo-Filho PP; Ribas RM
J Med Microbiol; 2014 Dec; 63(Pt 12):1679-1687. PubMed ID: 25261066
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
[TBL] [Abstract][Full Text] [Related]
9. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
Balandin B; Ballesteros D; Ruiz de Luna R; López-Vergara L; Pintado V; Sancho-González M; Soriano-Cuesta C; Pérez-Pedrero MJ; Asensio-Martín MJ; Fernández-Simón I; Rodríguez-Serrano D; Silva A; Chicot M; Iranzo R; Martínez-Sagasti F; Royuela A
Int J Antimicrob Agents; 2021 Mar; 57(3):106270. PubMed ID: 33347991
[TBL] [Abstract][Full Text] [Related]
10. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
Gentry CA; Williams RJ
Int J Antimicrob Agents; 2017 Mar; 49(3):333-338. PubMed ID: 28108367
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
12. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.
Hattemer A; Hauser A; Diaz M; Scheetz M; Shah N; Allen JP; Porhomayon J; El-Solh AA
Antimicrob Agents Chemother; 2013 Aug; 57(8):3969-75. PubMed ID: 23733476
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
14. Clinical characterization of breakthrough bacteraemia: a survey of 392 episodes.
López Dupla M; Martinez JA; Vidal F; Almela M; López J; Marco F; Soriano A; Richart C; Mensa J
J Intern Med; 2005 Aug; 258(2):172-80. PubMed ID: 16018794
[TBL] [Abstract][Full Text] [Related]
15. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
Albasanz-Puig A; Gudiol C; Parody R; Tebe C; Akova M; Araos R; Bote A; Brunel AS; Calik S; Drgona L; García E; Hemmati P; Herrera F; Ibrahim KY; Isler B; Kanj S; Kern W; Maestro de la Calle G; Manzur A; Marin JI; Márquez-Gómez I; Martín-Dávila P; Mikulska M; Montejo JM; Montero M; Morales HMP; Morales I; Novo A; Oltolini C; Peghin M; Del Pozo JL; Puerta-Alcalde P; Ruiz-Camps I; Sipahi OR; Tilley R; Yáñez L; Gomes MZR; Carratalà J;
BMJ Open; 2019 May; 9(5):e025744. PubMed ID: 31129580
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Clin Microbiol Infect; 2005 May; 11(5):415-8. PubMed ID: 15819873
[TBL] [Abstract][Full Text] [Related]
17. Results of an early intervention programme for patients with bacteraemia: analysis of prognostic factors and mortality.
Del Arco A; Olalla J; de la Torre J; Blázquez A; Montiel-Quezel N; Prada JL; Rivas F; García-Alegría J; Fernández-Sánchez F
BMC Infect Dis; 2017 May; 17(1):360. PubMed ID: 28532458
[TBL] [Abstract][Full Text] [Related]
18. Resistance profiles and risk factors of resistant microorganisms in bacteraemia of abdominal origin.
Martín Jaramago J; Armero Ibáñez R; Camarena Miñana JJ; Morales Suárez-Varela M
Rev Esp Anestesiol Reanim; 2017 Nov; 64(9):490-498. PubMed ID: 28434558
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Fattah MA; Haquin J; MacGowan A; Grier S; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Maurer S; Rodriguez-Bano J; Morales I; Oliver A; de Gopegui ER; Cano A; Machuca I; Gozalo-Marguello M; Martinez-Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
Int J Antimicrob Agents; 2020 Feb; 55(2):105847. PubMed ID: 31770625
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]